CSPC Pharmaceutical Expands On-Market Buybacks for 2026 Share Award Scheme
Claim 55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
CSPC Pharmaceutical Group ( (HK:1093) ) has shared an update.
CSPC Pharmaceutical Group has disclosed that, under its 2026 Restricted Share Award Scheme, a trustee purchased 2.8 million shares on the market on 16 June 2026 to hold in trust for selected participants. The purchase, representing about 0.02% of shares in issue and costing roughly HK$19.75 million at an average price of HK$7.0549 per share, increases the trustee’s total holdings under the scheme to 24.26 million shares, or about 0.21% of the company.
In parallel, the trustee of CSPC’s 2018 Share Award Scheme holds 117 million shares on trust, underscoring the company’s ongoing use of equity-based incentives to retain and motivate key personnel. The board stated it will continue to exercise discretion over the number of shares awarded and any further on-market purchases under both the 2018 and 2026 share award schemes, signaling continued alignment of management and employee interests with shareholders.
The most recent analyst rating on (HK:1093) stock is a Buy
with a HK$13.05 price target.
To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock,
see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong-incorporated pharmaceutical company listed on the Stock Exchange of Hong Kong. The group focuses on the research, development, manufacture and sale of a broad range of pharmaceutical products, serving both domestic and international healthcare markets.
Average Trading Volume: 95,314,340
Technical Sentiment Signal: Hold
Current Market Cap: HK$83.28B
For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.
